Search results for " Registries"

showing 10 items of 114 documents

Relationship between carotid intima-media thickness and non valvular atrial fibrillation type.

2015

OBJECTIVE: Carotid intima-media thickness (cIMT) is a surrogate marker of subclinical atherosclerosis and it is able to predict both coronary and cerebral vascular events. No data exist on the association between cIMT and non valvular atrial fibrillation (NVAF) type. We conduct this study with the aim to analyze the association between abnormal cIMT and NVAF type. METHODS: A cross-sectional study of the "Atrial fibrillation Registry for Ankle-brachial index Prevalence Assessment-Collaborative Italian Study (ARAPACIS)" has been performed. Among 2027 patients enrolled in the ARAPACIS, 673 patients, who underwent carotid ultrasound examination to assess cIMT, were included in the study. RESULT…

Carotid Artery DiseasesMaleRegistrieSettore MED/09 - Medicina Internagenetic structuresCross-sectional studycarotid intima-media thickness; non valvular atrial fibrillation; ARAPACIScarotid atherosclerosisPredictive Value of TestComorbiditySubclinical atherosclerosiintima-media-thicknessCarotid intima-media thickneRisk FactorsAtrial Fibrillation80 and overPrevalencenonvalvular atrial fibrillation; intima-media-thickness; carotid atherosclerosisRegistriesCarotid intima-media thicknessStrokeAged 80 and overCarotid intima-media thickness; Paroxysmal non valvular atrial fibrillation; Persistent/permanent non valvular atrial fibrillation; Subclinical atherosclerosis; Aged; Aged 80 and over; Ankle Brachial Index; Asymptomatic Diseases; Atrial Fibrillation; Carotid Artery Diseases; Carotid Artery Common; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Female; Humans; Italy; Linear Models; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Prevalence; Registries; Risk Factors; Carotid Intima-Media ThicknessMedicine (all)Atrial fibrillationMiddle AgedCommonItalyPredictive value of testsnon valvular atrial fibrillationCardiologycardiovascular systemLinear ModelFemaleCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyLogistic ModelCarotid Artery CommonPersistent/permanent non valvular atrial fibrillationparoxysmal non valvular atrial fibrillation; persistent/permanent non valvular atrial fibrillation; subclinical atherosclerosis; carotid intima-media thicknessPredictive Value of TestsParoxysmal non valvular atrial fibrillationInternal medicinemedicineHumansAnkle Brachial Indexcardiovascular diseasesSubclinical atherosclerosisCarotid intima-media thickness; Paroxysmal non valvular atrial fibrillation; Persistent/permanent non valvular atrial fibrillation; Subclinical atherosclerosisAgedCross-Sectional StudieAsymptomatic DiseaseCarotid Artery DiseaseChi-Square Distributionbusiness.industrySurrogate endpointRisk Factornonvalvular atrial fibrillationmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareComorbidityParoxysmal Non Valvular Atrial Fibrillation Persistent/Permanent Non Valvular Atrial Fibrillation Subclinical Atherosclerosis Carotid Intima-Media ThicknessCross-Sectional StudiesLogistic ModelsIntima-media thicknessAsymptomatic DiseasesLinear ModelsARAPACISCarotid ArterybusinessChi-squared distribution
researchProduct

Rationale, design and methods of CTCA-PRORECAD (Computed Tomography Coronary Angiography Prognostic Registry for Coronary Artery Disease): a multicen…

2013

PURPOSE: This study was done to assess the prognostic value of computed tomography coronary angiography (CTCA) in a large multicentre population of patients with suspected coronary artery disease (CAD) and, in particular, its incremental value compared with traditional methods for risk stratification. MATERIALS AND METHODS: This is a retrospective observational study that began in January 2003 conducted on patients with suspected CAD assessed with CTCA on the basis of symptoms (chest pain, dyspnoea) and/or abnormal or equivocal stress test and/or a high cardiovascular risk profile. The participating centres will provide data obtained with CTCA performed with 16-slice or higher equipment. Ex…

Coronary angiographyMaleContrast MediaComputed tomographyCoronary DiseaseCoronary AngiographyCoronary artery diseaseComputed tomography coronary angiographyCoronary artery diseaseComputer-AssistedRisk FactorsRegistriesTomographyNeuroradiologyeducation.field_of_studymedicine.diagnostic_testcomputed tomography coronary angiography; coronary artery disease; prevalence of disease; prognosis; registry; risk stratificationRadiographic Image InterpretationInterventional radiologyGeneral MedicineMiddle AgedPrognosisX-Ray ComputedResearch DesignRisk stratificationCardiologyPrevalence of diseaseRadiographic Image Interpretation Computer-AssistedFemaleRadiologymedicine.medical_specialtyRegistryPrognosiEndpoint DeterminationPopulationRisk AssessmentComputed tomography coronary angiography; Coronary artery disease; Prevalence of disease; Prognosis; Risk stratification; Registry; Analysis of Variance; Contrast Media; Coronary Disease; Endpoint Determination; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiographic Image Interpretation Computer-Assisted; Retrospective Studies; Risk Assessment; Risk Factors; Coronary Angiography; Registries; Research Design; Tomography X-Ray ComputedInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingeducationRisk stratificationProportional Hazards ModelsRetrospective StudiesAnalysis of Variancebusiness.industrymedicine.diseasebusinessTomography X-Ray ComputedLa Radiologia medica
researchProduct

Paper 6: EUROCAT member registries: organization and activities.

2011

BACKGROUND: EUROCAT is a network of population-based congenital anomaly registries providing standardized epidemiologic information on congenital anomalies in Europe. There are three types of EUROCAT membership: full, associate, or affiliate. Full member registries send individual records of all congenital anomalies covered by their region. Associate members transmit aggregate case counts for each EUROCAT anomaly subgroup by year and by type of birth. This article describes the organization and activities of each of the current 29 full member and 6 associate member registries of EUROCAT. METHODS: Each registry description provides information on the history and funding of the registry, popu…

EmbryologyPediatricsDatabases FactualENGLANDMultiple congenital anomalyAge limit0302 clinical medicinePregnancyPrenatal DiagnosisPrevalenceConfidentiality030212 general & internal medicineRegistriesRISK0303 health scienceseducation.field_of_studyFetal death030305 genetics & hereditycongenital anomaly registriesGeneral MedicineorganizationStillbirthascertainment3. Good healthComputer algorithmEuropeCONGENITAL-ANOMALIESPrenatal screeningEvaluation Studies as TopicPopulation SurveillanceCommittee MembershipFemaleMedical emergencymedicine.medical_specialtyPopulationPopulation basedCongenital Abnormalities03 medical and health sciencesmedicineHumanseducationFetal DeathInternetbusiness.industryRENACAbortion InducedEstados de Saúde e de Doençamedicine.diseasepopulation-basedcongenital anomalies ; Europe ; multiple congenital anomaly ; computer algorithm ; classification ; surveillance ; etiologyPediatrics Perinatology and Child HealthbusinessDevelopmental BiologyBirth defects research. Part A, Clinical and molecular teratology
researchProduct

Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Regist…

2019

BACKGROUND: We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. METHODS: Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T.…

Graft RejectionMalemedicine.medical_specialtyTime FactorsDrug Compoundingmedicine.medical_treatmentCalcineurin InhibitorsMedizinMEDLINEchemical and pharmacologic phenomenaLiver Transplant030230 surgeryLiver transplantationRisk AssessmentTacrolimusall contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA)03 medical and health sciences0302 clinical medicineRisk FactorsProlonged releaseInternal medicinemedicineHumansAged; Calcineurin Inhibitors; Delayed-Action Preparations; Drug Compounding; Europe; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Male; Middle Aged; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Tacrolimus; Time Factors; Treatment Outcome; Liver TransplantationRegistriesAgedRetrospective StudiesTransplantationbusiness.industryGraft SurvivalImmunosuppressionRetrospective cohort studyMiddle AgedTacrolimusSettore MED/18Liver Transplantation3. Good healthEuropeTreatment Outcomesurgical procedures operativeDelayed-Action PreparationsFemale030211 gastroenterology & hepatologyTransplant patientbusinessRisk assessmentImmunosuppressive AgentsTransplantation
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

The impact of the Eurofever criteria and the new Infevers MEFV classification in real life: results from a large international FMF cohort

2022

INTRODUCTION: New Eurofever/PRINTO classification criteria (EPCC) for Familial Mediterranean Fever (FMF) and other recurrent fevers have been recently developed, together with the classification of the pathogenicity of MEFV variants. OBJECTIVES: To evaluate the impact in real life of both the EPCC and INSAID pathogenicity classification of MEFV variants in the large international Eurofever FMF cohort. METHODS: Baseline demographic, genetic and clinical data of FMF patients included in the Eurofever registry were evaluated. The EPCC and the 2018 INSAID classification for MEFV variants were applied in all eligible FMF patients. RESULTS: Since November 2009, clinical information was available …

Male*Genetic analysis*Autoinflammatory diseasesPyrinFamilial Mediterranean fever*Classification criteriaCohort StudiesAnesthesiology and Pain MedicineRheumatologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAMutation*Familial mediterranean feverHumansFemale*RegistryRegistriesAutoinflammatory diseases Classification criteria Familial mediterranean fever Genetic analysis Recurrent fevers Registry Cohort Studies Colchicine Female Humans Male Mutation Pyrin Registries Familial Mediterranean FeverColchicine*Recurrent fevers
researchProduct

Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

2017

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries. Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was calcu…

Male0301 basic medicinePathologypopulation-based registriesCancer Care Facilities; Delivery of Health Care; Europe; Female; Hospitalization; Humans; Incidence; Male; Neoplasms; Rare Diseases; Registries; Survival Rate; Oncology0302 clinical medicineNeoplasmsMedicineRegistriesmedia_commonTumors -- Treatment -- Europeeducation.field_of_studyRelative survivalIncidenceIncidence (epidemiology)RARECARE projectEuropeHospitalizationSurvival RateOncology030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.medical_specialtyHealth surveysPopulationSocio-culturaleCancer Care Facilities03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingHumansmedia_common.cataloged_instanceCancer -- MortalityRisk factorEuropean unioneducationSurvival rateOncology cancer burden incidence rare cancerpopulation-based registriesrare cancers cancer registry RARECAREbusiness.industryRare cancerCancer -- Patients -- Long-term careCancer registry030104 developmental biologycancer burdenbusinessDelivery of Health CareDemographyRare disease
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Reg…

2018

Recent evidence supports the concept that progression of chronic heart failure (CHF) depends upon an imbalance of catabolic forces over the anabolic drive. In this regard, multiple hormonal deficiency syndrome (MHDS) significantly has impacts upon CHF progression, and is associated with a worse clinical status and increased mortality. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Therapy in Heart Failure) Registry (clinicaltrial.gov = NCT02335801) tests the hypothesis that anabolic deficiencies reduce survival in a large population of mild-to-moderate CHF patients. The T.O.S.CA. Registry is a prospective multicenter observational study coordinated by “Federico II” Un…

MaleAnabolismmedicine.medical_treatment030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawClinical endpointMedicineDeficiency Disease030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyTestosteroneAnabolic deficiency; Chronic heart failure; Heart failure metabolism; Multiple hormonal deficiency syndrome; Registry; Aged; Biomarkers; Chronic Disease; Deficiency Diseases; Disease Progression; Female; Heart Failure; Humans; Italy; Male; Metabolic Diseases; Middle Aged; Prospective Studies; Registries; Internal Medicine; Emergency MedicineMiddle AgedItalyEmergency MedicineDisease ProgressionFemaleHumanmedicine.medical_specialtyRegistryAnabolic deficiencyAnabolic deficiency Chronic heart failure Heart failure metabolism Multiple hormonal deficiency syndrome RegistrySocio-culturaleHeart failure metabolism03 medical and health sciencesMetabolic DiseasesInternal medicineInternal MedicineHumansAgedHeart Failurebusiness.industryMultiple hormonal deficiency syndromeSettore MED/13 - ENDOCRINOLOGIABiomarkermedicine.diseaseChronic heart failureMetabolic DiseaseProspective StudieHeart failureChronic DiseaseObservational studyHormone therapybusinessDeficiency DiseasesBiomarkersInternal and emergency medicine
researchProduct

Trends in net survival from stomach cancer in six European Latin countries: results from the SUDCAN population-based study

2016

IF 2.415; International audience; Gastric cancers are a clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from gastric cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and explore the trends in net survival and in the dynamics of the excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 200…

MaleCancer ResearchDatabases FactualEpidemiology0302 clinical medicineBelgiumEpidemiologyRegistries030212 general & internal medicineYoung adultStomach cancerNet SurvivalAged 80 and overstomach cancerMiddle Aged3. Good healthSurvival RateEuropeTrend analysisItalyOncologyPopulation Surveillance030220 oncology & carcinogenesisFemaleFrancenet survivalSwitzerlandAdultmedicine.medical_specialtyAdolescent[SDV.CAN]Life Sciences [q-bio]/CancerYoung Adult03 medical and health sciencesStomach NeoplasmsmedicineHumansSurvival rateexcess mortality rateAgedPortugalbusiness.industryCarcinomaPublic Health Environmental and Occupational HealthCancermedicine.diseaseEstrogenPopulation based studyGastric-cancerSpaincancer registriesSurgerytrend analysisbusinessDemography
researchProduct